Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The commercial stage pharmaceutical company focused on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol) confirmed to investors that the TGA has registered Feraccru® as a treatment in the Australian Register of Thera...
Product Name : Feraccru
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 03, 2021
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Beijing Aosaikang Pharmaceutical
Deal Size : $62.8 million
Deal Type : Licensing Agreement
China licence agreement for Feraccru/Accrufer
Details : Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .
Product Name : Feraccru
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : $11.4 million
August 01, 2020
Lead Product(s) : Ferric Maltol
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Beijing Aosaikang Pharmaceutical
Deal Size : $62.8 million
Deal Type : Licensing Agreement